Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter.
Michael LimMichael WellerAhmed IdbaïhJoachim SteinbachGaetano FinocchiaroRaju R RavalGeorge AnsstasJoachim BaehringJennie W TaylorJerome HonnoratKevin PetreccaFilip De VosAntje WickAshley SumrallSolmaz SahebjamIngo K MellinghoffMasashi KinoshitaMustimbo RobertsRuta SlepetisDeepti WaradDavid LeungMichelle LeeDavid A ReardonAntonio OmuroPublished in: Neuro-oncology (2022)
NIVO added to RT + TMZ did not improve survival in patients with newly diagnosed glioblastoma with methylated or indeterminate MGMT promoter. No new safety signals were observed.